Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELAN: Early vs Late DOACs in Post-Ischaemic Stroke
NCT03148457Completed
- Sponsor
- Insel Gruppe
- Start
- Nov 2017
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Randomised, single-blind trial of rivaroxaban, dabigatran, apixaban and edoxaban in Atrial fibrillation (AFib) and ischemic stroke (2 arms), sponsored by Insel Gruppe. Primary endpoint: Composite of major bleeding, recurrent ischaemic stroke, systemic embolism and/or vascular death at 30 days. Started Nov 2017; status: completed.
02
Drugs
rivaroxabandabigatranapixabanedoxaban
03
Conditions
Atrial fibrillation (AFib)ischemic stroke
Beyond the preview
Go deeper on NCT03148457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03148457.